The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.
Also called NCT04365517
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT04365517
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT04365517. Randomized; no masking; primary purpose treatment. Start 2021-12-29 (anticipated); primary completion 2022-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
- Acronym
- SIDIACO
- Condition
- Covid19
- Condition
- Diabetes Mellitus, Type 2
- Condition
- CKD (chronic kidney disease)
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- University of Milan
Record details
- Record id
cardio:ct-nct04365517- Content hash
665ead11adc3390424b1cbedabd475e0eea679bf663bf275cfac6f1f177092b1